ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1482

Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis

John Carrino1, Timothy McAlindon2, Eric Vignon3, Mark Brown4, Aimee Burr4, Robert Fountaine4, Glenn Pixton5, Lars Viktrup6, Christine West7 and Kenneth Verburg8, 1Hospital for Special Surgery, Hackensack, NJ, 2Tufts Medical Center, Boston, MA, 3Université Claude Bernard Lyon 1, Pierre Benite, France, 4Pfizer Inc., Groton, CT, 5Pfizer Inc., Morrisville, NC, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Groton

Meeting: ACR Convergence 2020

Keywords: clinical trial, Osteoarthritis, pain

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 8, 2020

Session Title: Osteoarthritis I: Clinical Trials (1482–1486)

Session Type: Abstract Session

Session Time: 4:00PM-4:50PM

Background/Purpose: Tanezumab, a monoclonal antibody that inhibits nerve growth factor, has been shown effective in the management of osteoarthritis (OA) pain.1,2 Due to the potential risk of rapidly progressive OA, recent phase 3 studies of subcutaneous tanezumab included a comprehensive prospective assessment of joint safety. The analyses summarized here include baseline population characteristics, adjudicated joint safety outcomes and sub-group analyses in the combined randomized, controlled, phase 3 OA tanezumab studies.

Methods: In study 1 (NCT02697773) patients received placebo, tanezumab 2.5 mg, or 2.5 mg then 5 mg (tanezumab 2.5/5 mg) over 16 weeks. In study 2 (NCT02709486) patients received placebo, tanezumab 2.5 mg, or tanezumab 5 mg over 24 weeks. In study 3 (NCT02528188) patients received tanezumab 2.5 mg, tanezumab 5 mg, or nonsteroidal anti-inflammatory drug (NSAID) over 56 weeks. Joint safety outcomes were adjudicated by a blinded external Adjudication Committee. The adjudicated composite joint safety endpoint (CJSE) included: primary osteonecrosis (ON), rapidly progressive OA type 1 (RPOA1) or type 2 (RPOA2), subchondral insufficiency fracture (SIF), or pathological fracture. Subgroups were cross-tabulated to investigate potential associations with outcomes descriptively with no formal statistical analysis.

Results: At baseline, maximum Kellgren-Lawrence (KL) grade of any joint and number of joints with KL grade ≥2 were similar across treatment groups (Table 1). A total of 451 patients were evaluated by the blinded adjudication committee; 145 were adjudicated to have a primary outcome which was a component of the CJSE: RPOA1 (69% 100/145), RPOA2 (17% 24/145), SIF (12% 18/145), and ON (2% 3/145) (Table 2). The proportion of patients with adjudicated CJSE was higher in tanezumab-treated patients relative to placebo or NSAID and the incidence increased with increasing dose of tanezumab. RPOA1 typically occurred in the knee and in joints with KL grade 2 or 3 OA at baseline, although there were four events in joints that were KL grade 0 at baseline (two each in the tanezumab 2.5 mg and 5 mg treatment groups). For RPOA2, the affected joint was approximately evenly split between the hip and knee with two patients having shoulder as the affected joint (one each in the tanezumab 5 mg and NSAID groups). Most RPOA2 events occurred in joints with KL grade 3 or 4 OA at baseline. RPOA2 was more often associated with a total joint replacement than RPOA1. Multiple subgroups were investigated to assess potential associations with CJSE, with possible associations noted for baseline disease severity and adverse events of arthralgia and joint swelling (Table 3).

Conclusion: Patients enrolled in the combined phase 3 OA tanezumab studies had moderate to severe OA. The proportion of patients with adjudicated CJSE was higher in tanezumab-treated patients relative to placebo or NSAID and the incidence increased with increasing dose of tanezumab. Subgroup analyses did not reveal an association of CJSE with efficacy response.

Table 1. Baseline disease characteristics, n (%)

Table 2. Adjudicated joint safety outcomes, n (%)

Table 3. Subgroups analyzed for potential association with adjudicated composite joint safety endpoint


Disclosure: J. Carrino, Covera Health, 5, Image Analysis Group, 5, Image Biopsy Lab, 5, Pfizer, 5, Simplify Medical, 5, Arthritis and Rheumatology journal, 9, Osteoarthritis Imaging journal, 9; T. McAlindon, Pfizer, 1, Sanofi Aventis US, 1, Kolon Tissuegene, 1, Samumed, 1, Seikagaku, 1, Kiniksa Pharmaceuticals, 1, Anika Therapeutics, 1; E. Vignon, Pfizer, 5; M. Brown, Pfizer, 1, 3; A. Burr, Pfizer Inc., 1, 2; R. Fountaine, Pfizer Inc., 1, 3, 4; G. Pixton, Pfizer Inc., 3, 4; L. Viktrup, Eli Lilly and Company, 1, 3; C. West, Pfizer Inc., 1, 3; K. Verburg, Pfizer Inc., 1, 2.

To cite this abstract in AMA style:

Carrino J, McAlindon T, Vignon E, Brown M, Burr A, Fountaine R, Pixton G, Viktrup L, West C, Verburg K. Joint Safety with Tanezumab: Integrated Analyses from Randomized Controlled Phase 3 Studies in Patients with Osteoarthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/joint-safety-with-tanezumab-integrated-analyses-from-randomized-controlled-phase-3-studies-in-patients-with-osteoarthritis/. Accessed April 11, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/joint-safety-with-tanezumab-integrated-analyses-from-randomized-controlled-phase-3-studies-in-patients-with-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.